Copyright Reports & Markets. All rights reserved.

Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Fostamatinib
    • 1.3.3 Sutimlimab
    • 1.3.4 Parsaclisib
    • 1.3.5 Rilzabrutinib
    • 1.3.6 lsatuximab
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital Pharmacy
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Online Pharmacy
  • 1.5 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size & Forecast
    • 1.5.1 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity (2021-2032)
    • 1.5.3 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Rigel Pharmaceuticals
    • 2.1.1 Rigel Pharmaceuticals Details
    • 2.1.2 Rigel Pharmaceuticals Major Business
    • 2.1.3 Rigel Pharmaceuticals Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.1.4 Rigel Pharmaceuticals Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Rigel Pharmaceuticals Recent Developments/Updates
  • 2.2 Apellis Pharmaceuticals, Inc.
    • 2.2.1 Apellis Pharmaceuticals, Inc. Details
    • 2.2.2 Apellis Pharmaceuticals, Inc. Major Business
    • 2.2.3 Apellis Pharmaceuticals, Inc. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.2.4 Apellis Pharmaceuticals, Inc. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Apellis Pharmaceuticals, Inc. Recent Developments/Updates
  • 2.3 Johnson & Johnson
    • 2.3.1 Johnson & Johnson Details
    • 2.3.2 Johnson & Johnson Major Business
    • 2.3.3 Johnson & Johnson Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.3.4 Johnson & Johnson Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Johnson & Johnson Recent Developments/Updates
  • 2.4 Sanofi
    • 2.4.1 Sanofi Details
    • 2.4.2 Sanofi Major Business
    • 2.4.3 Sanofi Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.4.4 Sanofi Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sanofi Recent Developments/Updates
  • 2.5 lncyte Corporation
    • 2.5.1 lncyte Corporation Details
    • 2.5.2 lncyte Corporation Major Business
    • 2.5.3 lncyte Corporation Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.5.4 lncyte Corporation Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 lncyte Corporation Recent Developments/Updates
  • 2.6 Teva Pharmaceutical lndustries Ltd
    • 2.6.1 Teva Pharmaceutical lndustries Ltd Details
    • 2.6.2 Teva Pharmaceutical lndustries Ltd Major Business
    • 2.6.3 Teva Pharmaceutical lndustries Ltd Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.6.4 Teva Pharmaceutical lndustries Ltd Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Teva Pharmaceutical lndustries Ltd Recent Developments/Updates
  • 2.7 Momenta Pharmaceuticals
    • 2.7.1 Momenta Pharmaceuticals Details
    • 2.7.2 Momenta Pharmaceuticals Major Business
    • 2.7.3 Momenta Pharmaceuticals Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.7.4 Momenta Pharmaceuticals Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Momenta Pharmaceuticals Recent Developments/Updates
  • 2.8 Alexion Pharmaceuticals, Inc.
    • 2.8.1 Alexion Pharmaceuticals, Inc. Details
    • 2.8.2 Alexion Pharmaceuticals, Inc. Major Business
    • 2.8.3 Alexion Pharmaceuticals, Inc. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.8.4 Alexion Pharmaceuticals, Inc. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Alexion Pharmaceuticals, Inc. Recent Developments/Updates
  • 2.9 lmmunovant
    • 2.9.1 lmmunovant Details
    • 2.9.2 lmmunovant Major Business
    • 2.9.3 lmmunovant Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.9.4 lmmunovant Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 lmmunovant Recent Developments/Updates
  • 2.10 F. Hoffmann-La Roche Ltd
    • 2.10.1 F. Hoffmann-La Roche Ltd Details
    • 2.10.2 F. Hoffmann-La Roche Ltd Major Business
    • 2.10.3 F. Hoffmann-La Roche Ltd Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Product and Services
    • 2.10.4 F. Hoffmann-La Roche Ltd Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates

3 Competitive Environment: Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment by Manufacturer

  • 3.1 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Revenue by Manufacturer (2021-2026)
  • 3.3 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Manufacturer Market Share in 2025
  • 3.5 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market: Overall Company Footprint Analysis
    • 3.5.1 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market: Region Footprint
    • 3.5.2 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market: Company Product Type Footprint
    • 3.5.3 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size by Region
    • 4.1.1 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Region (2021-2032)
    • 4.1.3 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Average Price by Region (2021-2032)
  • 4.2 North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value (2021-2032)
  • 4.3 Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value (2021-2032)
  • 4.5 South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Type (2021-2032)
  • 5.2 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Type (2021-2032)
  • 5.3 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Application (2021-2032)
  • 6.2 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Application (2021-2032)
  • 6.3 Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Type (2021-2032)
  • 7.2 North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Application (2021-2032)
  • 7.3 North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size by Country
    • 7.3.1 North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Type (2021-2032)
  • 8.2 Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Application (2021-2032)
  • 8.3 Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size by Country
    • 8.3.1 Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size by Region
    • 9.3.1 Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Type (2021-2032)
  • 10.2 South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Application (2021-2032)
  • 10.3 South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size by Country
    • 10.3.1 South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size by Country
    • 11.3.1 Middle East & Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Drivers
  • 12.2 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Restraints
  • 12.3 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment
  • 13.3 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Typical Distributors
  • 14.3 Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, lncyte Corporation, Teva Pharmaceutical lndustries Ltd, Momenta Pharmaceuticals, Alexion Pharmaceuticals, Inc., lmmunovant, F. Hoffmann-La Roche Ltd, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Fostamatinib
    Sutimlimab
    Parsaclisib
    Rilzabrutinib
    lsatuximab
    Market segment by Application
    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy
    Major players covered
    Rigel Pharmaceuticals
    Apellis Pharmaceuticals, Inc.
    Johnson & Johnson
    Sanofi
    lncyte Corporation
    Teva Pharmaceutical lndustries Ltd
    Momenta Pharmaceuticals
    Alexion Pharmaceuticals, Inc.
    lmmunovant
    F. Hoffmann-La Roche Ltd
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment, with price, sales quantity, revenue, and global market share of Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment from 2021 to 2026.
    Chapter 3, the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment.
    Chapter 14 and 15, to describe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment sales channel, distributors, customers, research findings and conclusion.

    Buy now